Thanks for posting Golfyeti, especially as a press release so I don't have to.

In addition to those three presentations at AHA, there is one more on apabetalone that is being presented at AHA as a meta-analysis by investigators not involved in Resverlogix or BETonMACE (to my knowledge). I posted about these 4 presentations last month and I just checked and all 4 are still on the schedule. Here is the info on the fourth one:

Session AC.APS.07 - Impact of Treatment Interventions on Stable Coronary Artery Disease: P1437 - Cardiovascular Benefits of Apabetalone: A Meta-analysis

Hang Long Li, Qi Feng, Yue Fei, bernard cheung, The Univ of Hong Kong, Hong Kong, Hong Kong

Nice to see the CTAD and ASN events on the schedule too!

BDAZ